title: Accelerated (malignant) hypertension: a study of 121 cases between 1974 and 1996.
abstract: A series of 121 consecutive cases with accelerated hypertension is presented. Forty-seven patients had essential hypertension. This diagnosis was confirmed during the follow-up, which lasted from 3 to 255 months (mean 63.1 +/- 58.1). The relationship between the effects of pharmacological treatment on high blood pressure (BP) and disease course were analyzed in accelerated essential hypertensive patients only, to avoid the imponderable influence of basic disease in secondary hypertension. In most cases, therapeutical effect on BP was monitored by multiple daily BP self-measurements. Since 1974, when this study was initiated, plasma creatinine concentration at admission showed a clear-cut decrease, especially after the introduction in the eighties of new hypotensive drugs. A sustained BP decrease assured a long-lasting preservation of renal function, if the initial functional loss was limited (plasma creatinine concentration of 2 mg/dl (176.8 mumol/l) or less). Renal function was preserved even if the BP decrease was not optimal and signs of relapsing malignant retinopathy were observed in the course of disease. Although the whole series showed a 12-year survival rate of about 69%, patients enrolled after 1980 had a 100% survival rate.
authors.affiliation: Postgraduate School of Nephrology, Institute of Clinical Medicine IV, University of Florence, Italy.
authors.forename: P T
authors.initials: PT
authors.lastname: Scarpelli
authors.forename: R
authors.initials: R
authors.lastname: Livi
authors.forename: G M
authors.initials: GM
authors.lastname: Caselli
authors.forename: L
authors.initials: L
authors.lastname: Di Maria
authors.forename: L
authors.initials: L
authors.lastname: Teghini
authors.forename: V
authors.initials: V
authors.lastname: Montemurro
authors.forename: G
authors.initials: G
authors.lastname: Toti
authors.forename: A
authors.initials: A
authors.lastname: Becucci
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D003000:Clonidine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D007674:Kidney Diseases / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage; D012164:Retinal Diseases / Q000517:prevention & control; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003404:Creatinine; D009543:Nifedipine; D003000:Clonidine